Trial
NCT03797261
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
Genentech, Inc.; Amgen
Condition
Acute Myeloid Leukemia
Intervention
Venetoclax
Why stopped
Safety
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-07